Jade Biosciences annual stock-based compensation
2020
2021
2022
2023
2024
2025
Jade Biosciences Stock-Based Compensation Growth & History (JBIO)
Jade Biosciences's stock-based compensation was $20.0M for fiscal 2025.
View full Jade Biosciences company overviewJade Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.0M | $8.7M | +76.90% |
| 2024 | 2024-12-31 | $11.3M | −$595,000 | −5.00% |
| 2023 | 2023-12-31 | $11.9M | $6.4M | +117.42% |
| 2022 | 2022-12-31 | $5.5M | $3.4M | +168.04% |
| 2021 | 2021-12-31 | $2.0M | $2.0M | +3422.41% |
| 2020 | 2020-12-31 | $58,000 | — | — |
Jade Biosciences quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.6M | $9.7M | +249.32% |
| Q1 2026 | 2026-03-31 | $7.4M | $5.0M | +205.61% |
| Q4 2025 | 2025-12-31 | $9.4M | $8.2M | +655.91% |
| Q3 2025 | 2025-09-30 | $4.3M | $2.3M | +114.43% |
| Q2 2025 | 2025-06-30 | $3.9M | $30,000 | +0.78% |
| Q1 2025 | 2025-03-31 | $2.4M | −$1.8M | −42.31% |
| Q4 2024 | 2024-12-31 | $1.2M | −$2.0M | −61.77% |
| Q3 2024 | 2024-09-30 | $2.0M | −$1.2M | −38.12% |
| Q2 2024 | 2024-06-30 | $3.9M | $831,000 | +27.39% |
| Q1 2024 | 2024-03-31 | $4.2M | $1.8M | +76.17% |
| Q4 2023 | 2023-12-31 | $3.3M | $1.5M | +88.03% |
| Q3 2023 | 2023-09-30 | $3.2M | $1.7M | +115.94% |
| Q2 2023 | 2023-06-30 | $3.0M | $1.8M | +147.88% |
| Q1 2023 | 2023-03-31 | $2.4M | $1.4M | +132.81% |
| Q4 2022 | 2022-12-31 | $1.7M | $875,000 | +102.46% |
| Q3 2022 | 2022-09-30 | $1.5M | $654,000 | +77.40% |
| Q2 2022 | 2022-06-30 | $1.2M | $903,000 | +281.31% |
| Q1 2022 | 2022-03-31 | $1.0M | $1.0M | +4352.17% |
| Q4 2021 | 2021-12-31 | $854,000 | — | — |
| Q3 2021 | 2021-09-30 | $845,000 | $824,000 | +3923.81% |
| Q2 2021 | 2021-06-30 | $321,000 | $315,000 | +5250.00% |
| Q1 2021 | 2021-03-31 | $23,000 | — | — |
| Q3 2020 | 2020-09-30 | $21,000 | — | — |
| Q2 2020 | 2020-06-30 | $6,000 | — | — |
Jade Biosciences stock-based compensation trends
Over the last five fiscal years, Jade Biosciences's stock-based compensation increased from $58,000 to $20.0M, a change of $20.0M. The latest reported quarter, Q2 2026, shows $13.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Jade Biosciences source filings ↗